NCT06508645 - Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

March 29, 2022

Study Completion Date

April 6, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

DWP14012 injection

"1. Part 1~ * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~ * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)"

Trial Locations (1)

03080

Seoul-National University Hospital, Seoul